Research Paper Volume 14, Issue 24 pp 9980—10008

Figure 4. The relationship between NLRP1/NLRP3 expression levels with clinical characteristics of patients with GC. In Kaplan Meier Plotter, high expression of NLRP1 was correlated with worse prognosis of GC patients in (A) Stage T2 (n = 241, OS, HR = 1.85, p = 0.0039), (B) Stage T3 (n = 204, OS HR = 1.461, p = 0.031). High expression of NLRP3 was correlated with worse prognosis of GC patients in (C) stage T2 (n = 241, OS, HR = 1.79, p = 0.011), (D) Stage T3 (n = 204, OS, HR = 1.57, p = 0.012). High expression of NLRP1 was correlated with worse prognosis of GC patients in (E, F) Stages N1+2+3 (n = 422, OS, HR = 1.62, p = 0.00036; PFS, HR = 1.76, p = 5e−04). High expression of NLRP3 was correlated with worse prognosis of GC patients in (G, H) Stages N1+2+3 (n = 422, OS, HR = 1.48, p = 0.0039; PFS, HR = 1.36, p = 0.019). (I–N) In TCGA, Expression level of NLRP1/NLRP3 has a significant correlation with tumor grade, cancer stage, and lymph node metastasis. ^*p < 0.05, ^**p < 0.01. Notes: Grade 1, Well differentiated (low grade); Grade 2, Moderately differentiated (intermediate grade); Grade 3, Poorly differentiated (high grade); Grade 4, Undifferentiated (high grade). N0, No regional lymph node metastasis; N1, Metastases in 1 to 3 axillary lymph nodes; N2, Metastases in 4 to 9 axillary lymph nodes; N3, Metastases in 10 or more axillary lymph nodes.